GO:0090370 negative regulation of cholesterol efflux: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090370 (negative regulation of cholesterol efflux) describes any process that decreases the frequency, rate or extent of cholesterol efflux, the directed movement of cholesterol out of a cell or organelle.
• The nuclear oxysterol receptor LXR alpha is a central transcriptional activator of cholesterol efflux, and its suppression reduces ABCA1 expression and efflux capacity.
• TRAK2 was identified as a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis, linking intracellular trafficking to efflux control.
• MMAB promotes negative feedback control of cholesterol homeostasis, providing a metabolic brake on cholesterol excess.
• Inflammatory and antirheumatic treatments can alter cell cholesterol efflux and the loading capacity of serum lipoproteins, showing that the process is responsive to immune and pharmacological signals.
• PBMC expression of genes involved in HDL metabolism and atherogenesis correlates with HDL cholesterol, making efflux regulation a clinically measurable trait.
Description
Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle, and it is the first step in reverse cholesterol transport, the pathway that returns excess cholesterol from peripheral tissues to the liver. The Gene Ontology term GO:0090370, negative regulation of cholesterol efflux, captures any process that decreases the frequency, rate or extent of this export. Because cholesterol overload in macrophages is a hallmark of atherosclerotic plaque formation, understanding what restrains efflux is as important as understanding what drives it. The term is therefore a focal point for cardiovascular, metabolic and inflammation research. Mechanistically, negative regulation of cholesterol efflux is not a single reaction but a regulatory node. It can be achieved by reducing the abundance or activity of the ATP-binding cassette transporters that mediate efflux, by altering the transcriptional programs that sustain them, or by changing the lipid and protein environment of the plasma membrane. The nuclear oxysterol receptor LXR alpha is a well-established positive regulator of efflux genes, so pathways that antagonize LXR alpha activity or its downstream targets are prime candidates for negative regulation. Post-transcriptional and trafficking mechanisms add further layers, as illustrated by TRAK2, a regulator of ABCA1 expression and HDL biogenesis. For researchers, GO:0090370 provides a controlled vocabulary to annotate experiments in which a gene, drug or condition reduces cholesterol efflux. It connects cell-biological measurements, such as radiolabeled cholesterol efflux assays, to systemic phenotypes such as HDL cholesterol levels and atherogenesis. This article reviews the definition, the known molecular players, the disease relevance and the CRISPR-based methods used to study negative regulation of cholesterol efflux.
negative regulation of cholesterol efflux At A Glance
| GO ID | GO:0090370 |
|---|---|
| GO term | negative regulation of cholesterol efflux |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that decreases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. |
| Major function | Restraining the export of cholesterol from cells or organelles, thereby influencing cellular cholesterol balance and reverse cholesterol transport. |
| Related process | Cholesterol efflux (the positively regulated process) and HDL metabolism. |
| Key regulators | LXR alpha, ABCA1, TRAK2, MMAB and inflammatory signaling pathways. |
| Disease relevance | Atherosclerosis, dyslipidemia, inflammatory arthritis and metabolic disease. |
What Is GO:0090370?
GO:0090370, negative regulation of cholesterol efflux, is a biological process term defined as any process that decreases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux itself is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle. In practice, annotating a gene or condition with GO:0090370 means that experimental evidence shows a reduction in the amount or rate of cholesterol leaving a cell or organelle, whether that reduction is caused by transcriptional, post-transcriptional, trafficking or metabolic mechanisms.
Why Is negative regulation of cholesterol efflux Important in Cell Biology?
Negative regulation of cholesterol efflux is important because the rate at which cells export cholesterol determines how much cholesterol accumulates in peripheral tissues, especially macrophages, and therefore how vulnerable an individual is to atherosclerotic cardiovascular disease. The process is also a point of intersection between lipid metabolism and immunity: inflammatory signals and antirheumatic treatments can change cell cholesterol efflux and the cholesterol-loading capacity of serum lipoproteins. Because HDL cholesterol levels are associated with the expression of HDL metabolism and atherogenesis genes in peripheral blood mononuclear cells, regulators of efflux are candidate biomarkers and drug targets. Studying GO:0090370 helps explain why some individuals with high HDL cholesterol still have impaired efflux, and it provides a framework for testing whether a candidate gene causally restrains cholesterol export.
• Controls macrophage foam cell formation, a initiating step in atherosclerosis.
• Determines the efficiency of reverse cholesterol transport and thus cardiovascular risk.
• Is modulated by inflammatory signaling, linking immunity to lipid handling.
• Responds to antirheumatic treatment, making it a pharmacodynamic readout.
• Is transcriptionally controlled by the oxysterol receptor LXR alpha.
• Involves intracellular trafficking regulators such as TRAK2 that affect ABCA1 and HDL biogenesis.
• Is subject to metabolic negative feedback through MMAB.
• Can be monitored in patient blood samples through PBMC gene expression.
• Provides a mechanistic explanation for dyslipidemia in chronic inflammatory disease.
• Offers targets for therapies aimed at increasing, rather than decreasing, cholesterol efflux.
What Happens During negative regulation of cholesterol efflux?
Transcriptional suppression of efflux transporters
In simple terms: The cell makes fewer cholesterol pumps because the instructions for building them are turned down.
The nuclear oxysterol receptor LXR alpha controls cellular cholesterol efflux by activating target genes, including the ABCA1 transporter, in response to oxysterol ligands. Negative regulation of cholesterol efflux can therefore occur when LXR alpha activity or its downstream transcriptional program is reduced, lowering ABCA1 abundance and the capacity of the cell to export cholesterol. This transcriptional layer is a major node through which metabolic and inflammatory signals converge on efflux.
Post-transcriptional and trafficking control of ABCA1
In simple terms: Even if the pump is made, it may never reach the cell surface where it works.
TRAK2 was identified as a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis, indicating that intracellular trafficking and post-transcriptional mechanisms can restrain efflux independently of transcription. Because ABCA1 must reach the plasma membrane to accept cholesterol from lipid-poor apolipoproteins, any process that delays its maturation, transport or stability will reduce efflux and thus fulfill the definition of GO:0090370.
Metabolic negative feedback on cholesterol homeostasis
In simple terms: When cholesterol is plentiful, the cell applies brakes to avoid overflowing.
MMAB promotes negative feedback control of cholesterol homeostasis, providing a metabolic mechanism that can limit cholesterol movement out of cells when sterol balance is perturbed. Such feedback ensures that efflux is tuned to the cell's cholesterol status rather than running constitutively, and it illustrates how a single enzyme can act as a brake on the efflux arm of cholesterol metabolism.
Inflammatory and pharmacological modulation
In simple terms: Inflammation and some medicines can change how readily cells release cholesterol.
Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells, showing that cytokine pathways can reshape cellular lipid handling in immune cells. In patients with spondylarthropathies, antirheumatic treatment alters cell cholesterol efflux and the loading capacity of serum lipoproteins, demonstrating that the negative regulation of efflux is pharmacologically tractable and clinically measurable. These observations place GO:0090370 at the interface of immunology and lipidology.
RhoA and the actin cytoskeleton in ABCA1-mediated efflux
In simple terms: The cell's internal skeleton can act as a gatekeeper for cholesterol release.
Inhibition of hydroxymethylglutaryl-CoA reductase regulates macrophage cholesterol efflux through a RhoA-dependent mechanism, linking the mevalonate pathway and actin cytoskeleton dynamics to ABCA1-mediated efflux. When RhoA signaling is active, efflux can be restrained; when it is inhibited, efflux increases. This provides a concrete example of a signaling process that negatively regulates cholesterol efflux at the level of transporter function and membrane organization.
Key Genes Involved in GO:0090370 negative regulation of cholesterol efflux
The following genes and proteins have been experimentally linked to the control of cholesterol efflux and are therefore relevant to GO:0090370.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCA1 | ATP-binding cassette transporter that mediates cholesterol efflux to lipid-poor apolipoproteins | Central effector of efflux; its suppression defines negative regulation |
| ABCG1 | Transporter that promotes cholesterol efflux to mature HDL particles | Efflux capacity marker in macrophage and PBMC studies |
| NR1H3 (LXR alpha) | Nuclear oxysterol receptor that transcriptionally activates efflux genes | Master positive regulator; its inhibition causes negative regulation of efflux |
| TRAK2 | Regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis | Novel trafficking-linked control point for efflux |
| MMAB | Enzyme promoting negative feedback control of cholesterol homeostasis | Metabolic brake on cholesterol handling |
| RHOA | Small GTPase linking mevalonate pathway signaling to ABCA1-mediated efflux | Mediates statin-sensitive regulation of macrophage efflux |
| HMGCR | Rate-limiting enzyme of cholesterol synthesis; its inhibition affects efflux via RhoA | Pharmacological entry point for modulating efflux |
| APOA1 | Primary acceptor of cholesterol exported by ABCA1 | Substrate for efflux assays and HDL biogenesis |
| IL23R | Interleukin-23 receptor; signaling impairs regulatory T cell stability and function | Links inflammatory signaling to cellular lipid handling |
| CETP | Cholesteryl ester transfer protein involved in HDL metabolism | Part of the HDL gene expression signature associated with efflux |
| SCARB1 | HDL receptor involved in selective cholesterol uptake | Contributes to cellular cholesterol balance |
| ABCA1 (PBMC context) | Efflux transporter expressed in peripheral blood mononuclear cells | Measurable in patient blood for biomarker studies |
| LXR target genes | Network of genes controlling efflux, absorption and excretion | Transcriptional readout of negative regulation |
| RhoA effectors | Downstream kinases and cytoskeletal regulators | Candidate modifiers of ABCA1 function |
| MMAB-related metabolic enzymes | Enzymes of cholesterol and bile acid metabolism | Feedback control of sterol balance |
| TRAK2-associated motors | Intracellular transport machinery | Determines ABCA1 delivery to the membrane |
How Is negative regulation of cholesterol efflux Regulated?
Negative regulation of cholesterol efflux is itself regulated at multiple levels. Transcriptionally, the LXR alpha oxysterol receptor controls efflux gene expression, so factors that reduce LXR alpha ligand availability or activity lower efflux. Post-transcriptionally, TRAK2 influences ABCA1 expression and HDL biogenesis, showing that trafficking and stability mechanisms can override transcriptional output. Metabolically, MMAB provides negative feedback on cholesterol homeostasis, coupling sterol status to efflux capacity. Signaling through RhoA downstream of HMGCR inhibition modulates ABCA1-mediated efflux in macrophages, linking the mevalonate pathway to transporter function. Inflammatory cytokines such as interleukin-23 act on immune cell populations and can indirectly reshape cholesterol handling, and antirheumatic drugs measurably change cell cholesterol efflux and lipoprotein loading capacity in patients. Together these layers allow the cell to tune cholesterol export to its metabolic, inflammatory and pharmacological context.
negative regulation of cholesterol efflux and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCA1 | Atherosclerosis and Tangier disease-like efflux defects | Macrophage-specific knockout and efflux assay |
| NR1H3 (LXR alpha) | Dyslipidemia and impaired reverse cholesterol transport | LXR alpha knockout or point-mutation cells treated with oxysterols |
| TRAK2 | HDL biogenesis and cardiovascular risk | TRAK2 knockout with ABCA1 trafficking readouts |
| MMAB | Cholesterol homeostasis and metabolic disease | MMAB knockout with sterol balance measurements |
| RHOA | Statin-responsive macrophage foam cell formation | RhoA knockout or constitutively active knock-in in macrophages |
Atherosclerosis and cardiovascular disease
Impaired cholesterol efflux from macrophages promotes foam cell formation and atherosclerotic plaque development, and the influence of HDL particles on cell cholesterol efflux varies under different pathological conditions. Because negative regulation of cholesterol efflux reduces the removal of cholesterol from arterial wall cells, it is mechanistically linked to atherogenesis. PBMC expression of genes involved in HDL metabolism and atherogenesis is associated with HDL cholesterol, providing a human biomarker context for efflux regulation.
Inflammatory and rheumatic disease
Chronic inflammation alters lipoprotein metabolism and cellular cholesterol handling. Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells, illustrating how cytokine pathways affect immune cell lipid biology. In spondylarthropathies, antirheumatic treatment changes cell cholesterol efflux and the loading capacity of serum lipoproteins, suggesting that efflux regulation is a modifiable component of inflammatory disease.
Metabolic and lipid disorders
Negative feedback control of cholesterol homeostasis by MMAB indicates that dysregulation of sterol metabolism can shift the balance between cholesterol synthesis, storage and export. Because LXR alpha controls the efflux program, conditions that alter oxysterol production or LXR alpha activity can reduce efflux and contribute to dyslipidemia. These mechanisms are relevant to metabolic syndrome and other disorders characterized by altered cholesterol trafficking.
From negative regulation of cholesterol efflux-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase cholesterol efflux? | CRISPR knockout in macrophage or hepatocyte cell lines followed by radiolabeled efflux assay |
| Does a specific point mutation in ABCA1 impair transporter function? | Point-mutation knock-in of ABCA1 variants |
| Does overexpression of a negative regulator reduce efflux? | Doxycycline-inducible overexpression cell model |
| Where does a regulator localize relative to ABCA1? | Tagged knock-in with fluorescent tag and live-cell imaging |
| Which transcriptional programs are altered when efflux is suppressed? | LXR alpha knockout or knockdown with RNA-seq |
| Can pharmacological treatment reverse negative regulation of efflux? | Patient-derived PBMC or macrophage cultures treated with antirheumatic drugs |
How to Study the negative regulation of cholesterol efflux Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled cholesterol efflux assay | Rate of cholesterol movement from cells to acceptors | Functional classification of GO:0090370 |
| RNA-seq | Transcriptome changes including ABCA1 and LXR targets | Identifying transcriptional negative regulation |
| qPCR gene panel | Expression of HDL metabolism and atherogenesis genes | PBMC biomarker studies |
| Western blot | ABCA1 protein abundance and stability | Post-transcriptional regulation |
| Fluorescence microscopy | Subcellular localization of ABCA1 or tagged regulators | Trafficking studies |
| Lipidomics / mass spectrometry | Cholesterol and oxysterol species | Metabolic feedback analysis |
| RhoA activity assay | GTPase activation state | Mevalonate pathway effects on efflux |
| Cytokine profiling | Inflammatory mediators such as IL-23 | Linking inflammation to cholesterol handling |
Cholesterol efflux assays
Radiolabeled or fluorescent cholesterol efflux assays measure the movement of cholesterol from cells to acceptor particles such as apoA-I or HDL. These assays are the direct functional readout for GO:0090370 and have been used to show that HDL particles from different pathological conditions vary in their ability to promote efflux. They are also used to test whether antirheumatic treatment changes cell cholesterol efflux and lipoprotein loading capacity.
Transcriptional and expression profiling
RNA-seq and targeted gene expression panels can quantify ABCA1, ABCG1 and other LXR alpha target genes to determine whether negative regulation occurs at the transcriptional level. PBMC expression of HDL metabolism and atherogenesis genes has been associated with HDL cholesterol, demonstrating the feasibility of blood-based expression profiling for efflux-related traits.
Protein trafficking and imaging
Fluorescence microscopy and biochemical fractionation can track ABCA1 localization and stability, which is particularly relevant when studying regulators such as TRAK2 that affect ABCA1 expression and HDL biogenesis. Tagged knock-in cell lines allow real-time visualization of transporter trafficking under conditions that suppress efflux.
Metabolic and lipidomic measurements
Mass spectrometry-based lipidomics and sterol balance measurements can quantify cholesterol species and intermediates, providing a metabolic context for negative feedback control by MMAB and for RhoA-dependent effects on ABCA1-mediated efflux. These methods complement functional efflux assays by revealing changes in the broader cholesterol pool.
How CRISPR Can Be Used to Study GO:0090370 negative regulation of cholesterol efflux
Knockout
CRISPR knockout of candidate genes such as ABCA1, NR1H3 (LXR alpha), TRAK2 or MMAB can test whether loss of the gene increases or decreases cholesterol efflux, directly assigning function to GO:0090370. Knockout macrophages are particularly useful because they model the foam cell phenotype relevant to atherosclerosis.
Point Mutation
Point-mutation knock-in can model disease-associated variants in efflux genes, such as ABCA1 missense mutations, to determine whether a single amino acid change impairs transporter function or regulation. This approach distinguishes loss-of-function from loss-of-regulation mechanisms.
Knock-in
Tagged knock-in of ABCA1 or TRAK2 with fluorescent or affinity tags enables tracking of protein localization, stability and interactions under conditions that suppress efflux. Knock-in of reporter cassettes downstream of LXR alpha target genes can provide a transcriptional readout of negative regulation.
Overexpression
Overexpression of candidate negative regulators, such as MMAB or RhoA pathway components, can test whether increased abundance is sufficient to reduce cholesterol efflux. Inducible overexpression systems allow dose- and time-dependent analysis of efflux suppression.
How EDITGENE Supports negative regulation of cholesterol efflux Research
Researchers studying negative regulation of cholesterol efflux-related genes often need to determine whether a candidate gene is causally involved in reducing cholesterol export, or whether the observed effect is secondary to changes in cholesterol synthesis, inflammation or cell viability. CRISPR-based models provide the cleanest way to establish causality, and EDITGENE offers a full pipeline from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cholesterol efflux research.
Frequently Asked Questions About negative regulation of cholesterol efflux
What is GO:0090370 negative regulation of cholesterol efflux?
GO:0090370 is a Gene Ontology biological process term defined as any process that decreases the frequency, rate or extent of cholesterol efflux, where cholesterol efflux is the directed movement of cholesterol out of a cell or organelle.
What genes are involved in negative regulation of cholesterol efflux?
Key genes include ABCA1, ABCG1, NR1H3 (LXR alpha), TRAK2, MMAB, RHOA and HMGCR, all of which have been linked experimentally to the control of cholesterol efflux.
How is cholesterol efflux negatively regulated?
It can be negatively regulated by reducing LXR alpha transcriptional activity, by impairing ABCA1 trafficking or stability through regulators such as TRAK2, by metabolic feedback through MMAB, or by RhoA-dependent signaling downstream of HMGCR.
Why is negative regulation of cholesterol efflux important in atherosclerosis?
Reduced cholesterol efflux from macrophages promotes foam cell formation and plaque development, so processes that negatively regulate efflux are mechanistically linked to atherogenesis.
Does inflammation affect cholesterol efflux?
Yes, inflammatory signaling such as interleukin-23 receptor activation affects immune cell function, and antirheumatic treatment changes cell cholesterol efflux and lipoprotein loading capacity in patients.
What is the role of LXR alpha in cholesterol efflux?
LXR alpha is a nuclear oxysterol receptor that transcriptionally activates cholesterol efflux genes including ABCA1, so its inhibition reduces efflux and constitutes negative regulation.
How can I measure negative regulation of cholesterol efflux in the lab?
Radiolabeled or fluorescent cholesterol efflux assays, RNA-seq of LXR target genes, Western blotting for ABCA1 and imaging of transporter trafficking are standard approaches.
What CRISPR models are used to study cholesterol efflux regulation?
Knockout, point-mutation knock-in, tagged knock-in and overexpression models of genes such as ABCA1, TRAK2 and MMAB are used to test causality in efflux regulation.
Is cholesterol efflux related to HDL cholesterol levels?
Yes, PBMC expression of genes involved in HDL metabolism and atherogenesis is associated with HDL cholesterol, and HDL particles influence cell cholesterol efflux under various pathological conditions.
Can antirheumatic drugs change cholesterol efflux?
Studies in spondylarthropathies show that antirheumatic treatment affects cell cholesterol efflux and the loading capacity of serum lipoproteins, indicating a pharmacological link to GO:0090370.
Conclusion
GO:0090370, negative regulation of cholesterol efflux, defines the processes that restrain the export of cholesterol from cells and organelles. It is mechanistically diverse, spanning transcriptional control by LXR alpha, trafficking regulation by TRAK2, metabolic feedback by MMAB and signaling through RhoA. Clinically, it is tied to atherosclerosis, inflammatory disease and dyslipidemia, and it can be measured in patient samples through efflux assays and gene expression profiling. For researchers, the term provides a precise annotation target for experiments that reduce cholesterol efflux. CRISPR knockout, point-mutation, knock-in and overexpression models, combined with functional efflux assays and omics readouts, offer a rigorous path to establish causality. EDITGENE supports these efforts with custom cell model generation, library screening and bioinformatics analysis.
References
- 1. Dergunova LV et al.. 2020. HDL cholesterol is associated with PBMC expression of genes involved in HDL metabolism and atherogenesis.. J Med Biochem 39(3):372-383 PMID: 33269026
- 2. Goedeke L et al.. 2021. MMAB promotes negative feedback control of cholesterol homeostasis.. Nat Commun 12(1):6448 PMID: 34750386
- 3. Asztalos BF et al.. 2017. Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.. J Lipid Res 58(6):1238-1246 PMID: 28420704
- 4. Lake NJ et al.. 2017. TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis.. Eur Heart J 38(48):3579-3587 PMID: 28655204
- 5. Jacobse J et al.. 2023. Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells.. Cell Rep 42(2):112128 PMID: 36807140
- 6. Hokstad I et al.. 2022. Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies.. J Clin Med 11(24) PMID: 36555946
- 7. Argmann CA et al.. 2005. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.. J Biol Chem 280(23):22212-21 PMID: 15817453
- 8. Venkateswaran A et al.. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha.. Proc Natl Acad Sci U S A 97(22):12097-102 PMID: 11035776
